Gluclazz MR

Gliclazide

Adults w/ NIDDM (type 2), in association w/ dietary measures & exercise, when these measures alone are not sufficient.

Initially 30 mg once daily, may be increased up to 120 mg/day. Interval between each dose increment should be at least 1 mth except in patients whose blood glucose has not reduced after 2 wk of treatment. Patients at risk of hypoglycemia Start at dose of 30 mg.

Should be taken with food: Do not crush/chew.

Hypersensitivity to gliclazide, other sulfonylurea, sulfonamides. Type 1 diabetes; diabetic pre-coma & coma, diabetic keto-acidosis. Treatment w/ miconazole. Severe renal or hepatic insufficiency. Lactation.

Hypoglycemia may occur during low-calorie diets, following prolonged or strenuous exercise, alcohol intake or if a combination of hypoglycemic agents is being used; following administration of sulfonylurea. Increased risk of hypoglycemia if patient refuses or (particularly in elderly subjects) is unable to cooperate; malnutrition, irregular mealtimes, skipping meals, periods of fasting or dietary changes; imbalance between physical exercise & carbohydrate intake; overdose of gliclazide; Certain endocrine disorders: thyroid disorders, hypopituitarism & adrenal insufficiency; concomitant administration of certain other medicinal products. Blood glucose control may be affected by St John's wort (Hypericum perforatum) preparations, fever, trauma, infection or surgical intervention. Concomitant treatment w/ fluoroquinolones, especially in elderly patients may cause disturbances in blood glucose, including hypoglycemia & hyperglycemia; careful monitoring of blood glucose is recommended. Assess blood glucose control w/ measurement of glycated Hb levels (or fasting venous plasma glucose). Patients w/ G6PD-deficiency & a non-sulfonylurea alternative should be considered. Patients w/ rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption. May affect the ability to drive or operate machinery. Renal insufficiency. Severe hepatic insufficiency. Pregnancy. Childn & adolescents.

Hypoglycemia. Sweating, clammy skin, anxiety, tachycardia, HTN, palpitations, angina pectoris & cardiac arrhythmia. GI disturbances, including abdominal pain, nausea, vomiting, dyspepsia, diarrhea, & constipation

Increased hypoglycemic effect w/ miconazole, phenylbutazone. Increased hypoglycemic reaction that may lead to the onset of hypoglycemic coma w/ alcohol. Increase blood glucose lowering effect w/ other antidiabetic agents (insulins, acarbose, metformin, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, GLP-1 receptor agonists), β-blockers, fluconazole, ACE inhibitors (captopril, enalapril), H2-receptor antagonists, MAOIs, sulfonamides, clarithromycin & NSAIDs. Diabetogenic effect of danazol. Increased blood glucose levels w/ high doses of chlorpromazine, glucocorticoids & tetracosactrin. Increased blood glucose levels due to β₂-agonist effects w/ ritodrine, salbutamol, terbutaline. Decreased exposure w/ St. John's wort (Hypericum perforatum) preparations. Concomitant use w/ fluoroquinolone may increase the risk of dysglycemia. Concomitant use may potentiate the effect of anticoagulant therapy (eg, warfarin).

Antidiabetic Agents

A10BB09 - gliclazide ; Belongs to the class of sulfonylureas. Used in the treatment of diabetes.

Rx